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Abstract

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic
inflammation that affects the joints. It occurs when the immune system attacks the
body's own tissues and organs. The precise cause of RA is not fully understood but
evidence suggests that genes, hormones and environmental factors could be involved.
It has been established that human leukocyte antigen (HLA) loci is a strong risk factor
of RA. Specifically, the shared epitope (SE) region of HLA-DRB1 and variations at
position 11 and 13 of HLA-DRB1 and position 77 of HLA-A have shown strong
association with RA. The hypothesis of this study was that these variations could be
associated with RA patients in the UAE. To study this, regions of the HLA-DRB1 and
HLA-A genes from RA and control samples from Fujairah Hospital were sequenced
and analyzed. Results indicated that there was minimal incidence of high risk HLADRB1 SE or variations at position 11 and 13 of HLA-DRB1 in these samples. An
asparagine at position 77 (Asn77) appeared to be a much strong biomarker for RA in
this population (Odds ratio = 20.52, p-value = 0.0001985). Additionally, missense
mutations Arg56 and Glu76 were also observed with significantly higher incidence in
RA samples. The relevance of these variations warrant further investigation. In
summary, HLA-A appears to be a stronger indicator of RA than HLA-DRB1 in the
samples analyzed.
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)Title and Abstract (in Arabic

التباين الوراثي ألليالت الكريات الدم البيض البشرية ( )HLAبين مرضى التهاب
المفاصل الروماتويدي في الفجيرة
الملخص

التهاب المفاصل الروماتويدي ( )RAهو مرض مناعي ذاتي يتميز بالتهاب مزمن
يصيب المفاصل .يحدث عندما يهاجم الجهاز المناعي أنسجة الجسم وأعضائه .السبب األساسي
لإلصابة بإلتهاب المفاصل الروماتيدي ليس مفهوما بالكامل ،لكن األدلة تشير إلى أن الجينات
والهرمونات والعوامل البيئية يمكن أن تكون سببا في ذلك .لقد ثبت أيضا أن مستضد كريات الدم
البيضاء البشرية ( ،)HLAهو عامل خطر وقوي اللتهاب المفاصل الروماتويدي .على وجه
التحديد ،أظهرت منطقة الحلقة المشتركة ( )SEمن  HLA-DRB1والتغيرات في الموضع 11
و 13من  HLA-DRB1والموقع  77من  HLA-Aارتبا ً
طا قويًا بالتهاب المفاصل الروماتيدي.
وقد وضعنا فرضية أن هذه االختالفات يمكن أن ترتبط بمرضى التهاب المفاصل الروماتويدي
في دولة اإلمارات العربية المتحدة .وعليه تم دراسة وتقييم تسلسل الحمض النووي HLA-
 DRB1و HLA-Aمن مرضى إلتهاب المفاصل الروماتيدي من مستشفى الفجيرة ومقارنتها
بعينات ألشخاص غير مصابيين بالمرض .أشارت النتائج إلى أن هناك نسبة ضئيلة من HLA-
 DRB1 SEعالية المخاطر وكذلك نسبة خطورة ضئيلة في االختالفات في الموضع  11و13
من  HLA-DRB1في هذه العينات .ظهر الحمض األميني (اسبرجين) في الموضع 77
( )Asn77ليكون عالمة حيوية قوية للمرض في هذه الفئة من السكان (نسبة األرجحية = ،20.52
القيمة  .)p = 0.0001985باإلضافة إلى ذلك؛ لوحظت طفرات خطأ في موقعيين آخريين
 Arg56و Glu76بنسبة أعلى بكثير في عينات في فئة المصابيين بالمرض .أهمية هذه
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االختالفات يستدعي المزيد من التحقيق .باختصار ،يبدو أن  HLA-Aهو مؤشر أقوى على RA
من  HLA-DRB1في العينات التي تم تحليلها.
مفاهيم البحث الرئيسية :التهاب المفاصل الروماتويدي ،مستضد كريات الدم البيضاء ،حلق
مشترك.HLA-A ،HLA-DRB1 ،
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Chapter 1: Introduction

1.1 Human Genome & Genetic Diversity
Deoxyribonucleic acids (DNA) is the carrier of genetic information in most
organisms. It is composed of four chemical bases: Adenine (A), Thymine (T), Cytosine
(C) and Guanine (G). The Human Genome Project (HGP) was a ground-breaking
undertaking that was initiated to determine the DNA sequence of the human genome
and to map chromosomes to show the specific locations of genes (Holers, 2013). The
first draft of the human genome sequence was completed in 2001. A natural extension
of the HGP was to determine the genetic diversity among individuals and populations.
Understanding genetic diversity in human population, and individual genetic
variations, has several applications including the evaluation of the predisposition to
genetic diseases, personalized medicine, pharmacology and even forensics (Smolen et
al., 2016). Genetic variations or mutations result from changes in nucleotide sequence
of the DNA; such as deletions, insertions, or even rearrangement of DNA sequences
in the genome. DNA sequencing is an important technique used to define the exact
order of nucleic acid bases to investigate gene function (Holers, 2013). The DNA of
humans are 99.9% identical and the 0.1% difference accounts for several phenotypic
variations and genetic disorders. While the genome plays a vital role encoding an
individual’s genetic makeup, the environment also critically impacts an individual. A
comprehensive understanding of gene-environment interactions for high incidence
diseases, especially in families and populations, such as type 2 diabetes, cardiovascular
diseases, sickle cell anemia, cancer, and autoimmune disorders, could help in early
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detection, treatment and management of these conditions (Cush et al., 2010; Entezami
et al., 2011; Genetics Home Reference, 2013). One such high incidence autoimmune
disease with genetic basis is rheumatoid arthritis (RA) (Smolen et al., 2016).

1.2 Overview of Rheumatoid Arthritis
RA is the second most predominant autoimmune disorder (Holers, 2013). RA
is defined as a chronic inflammatory joint disease affecting, in particular, hands and
feet leading to cartilage and bone erosion (Smolen et al., 2016). It occurs when the
immune system attacks the body's own tissues and organs. RA is estimated to be found
in up to 1% of the population (Choy, 2012; Oka et al., 2014; Saxena et al., 2017;
Smolen et al., 2016). It is more common in women than in men, with a rate of two to
three times more in women, which may be related to hormonal factors (Genetics Home
Reference, 2013; Boekel et al., 2001). Lower prevalence rates of RA have been
described in Asian countries and rural Africa. The highest prevalence rate was
described in American and European populations (Carmona et al., 2002).
Geographical factors also play a role in RA since environmental factors are not equally
distributed. In this case, area of residency, nutritional factors, socioeconomic factors
and other factors affect the prevalence of RA (Martín et al., 2011). The general public
associates the term “arthritis” with pain and stiffness in joints. Arthritis in Greek means
inflammation (itis) of the joints (arthron). This term describes a collection of more than
hundred joints disorders without inflammation (Shlotzhauer et al., 2014). The term
“rheuma” made its first appearance in the first century referring to a substance, derived
from phlegm that flows in the body. It was believed to originate in the brain and flowed
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to various parts of the body causing ailments (West, 2014). The symptoms of RA
include pain, swelling, and stiffness of the joint, while in serious cases the
inflammation affects the bone, cartilage, and other tissues within the joint (Cush et al.,
2010).
RA is caused by a combination of genetic and environmental factors; however,
in many cases the precise etiology is unknown. Variations in several genes have been
studied as a risk factor for RA (Genetics Home Reference, 2013). Most of the genes
implicated are known or thought to be involved in immune system function.

1.3 History of Rheumatoid Arthritis
RA was first described by Augustin Jacob Landré-Beauvais in 1800 at an
asylum in France. He noticed the condition in poor patients, and suggested that the
disease is gender-related as it affected women more than men. He thought that it was
related to gout, which was then associated mostly with affluent patients. Thus, he
called it Primary Asthenic Gout. However, his explanation of RA as gout, did not
satisfy researchers in the field (Cush et al., 2010; Shlotzhauer et al., 2014). Sir Alfred
Baring Garrod, an English physician during the mid to late 19th century, was the first
person who differentiated gout from other arthritic conditions. His discovery was that
patients with gout have uric acid in their blood, which was not the case in patients with
arthritic conditions. In 1859, Sir Alfred published his classification of RA as a distinct
disorder in a manuscript titled “Treatise on Nature of Gout and Rheumatic Gout”
(Cush et al., 2010).
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Fifty years later, Sir Archibald Edward Garrod, the fourth son of Sir Alfred
Baring Garrod, wrote about his father’s discovery in a book titled “A Treatise on
Rheumatism and Rheumatoid Arthritis”. He was the first to use the term “Rheumatoid
Arthritis” when referring to this disease. He demonstrated that RA appears during a
period that was marked by increase in pollution, dietary changes, and lifestyle
transformations. In his book, he suggested that RA is a problem inherited from one’s
ancestors. He concluded this by studying skeletons found in some graves.
Unfortunately, his book lacked profound evidence (Cush et al., 2010; Shlotzhauer et
al., 2014). In Native American skeletons of the Mississippi River valley, RA had been
identified as far back as 4500 BC. Some researchers demonstrated that RA originated
as an infection in a small group of Native Americans; then it spread worldwide (Koehn
et al., 2002).
In 1912, Frank Billings suggested that RA was a response to chronic infection.
Scientists tried to find a link between different types of infections and the development
of RA. By the end of the 1920s, the culprit was thought to be tuberculosis and some
other bacteria like Streptococcus and Mycoplasma. Later, medical research focused on
viruses, rubella, and parvoviruses.
In the 20th century, some researchers suggested that bacteria that inhabit our
mouth and digestive tracts could cause an abnormal response of the immune system
which may lead to the development of RA (Boekel et al., 2001). In the mid-20th
century, investigators began using X-rays as a popular technique for comparing skeleta
of living patients. Their observations were dependent on the nature of soft tissue found
in a living patient. Therefore, it was suggested that the signs symptomatic of RA
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damage seen on dry skeletons may not have been produced by RA (Cush et al., 2010).
In 1940, Norwegian Eric Waaler discovered the Rheumatoid Factor (RF)
autoantibodies (Brink et al., 2016; Cantagrel & Degboe, 2016). RFs are autoantibodies
against the Fc domain of immunoglobulin G (IgG). For over half a century, RFs have
been used as a key marker of RA. 1.4 Genetic History of Rheumatoid Arthritis

A large body of evidence suggests that there is an association between human
leukocyte antigen (HLA) alleles and RA (Cantagrel & Degboe, 2016; Cush et al.,
2010; Weisman, 2011). It is considered to be the strongest genetic risk factor for the
disease (Drongelen & Holoshitz, 2017). In 1977, Andrew J. McMichael and colleagues
reported that there was an increased frequency of occurrence of Human Leukocyte
Antigen (HLA)-Cw3 and HLA-Dw4 proteins in RA patients (Choy, 2012). RJ.
Winchester from the New York Sinai School of Medicine studied populations of
patients with RA and families with multiple cases of RA, and provided definitive
evidence that susceptibility to the disease is determined both by genetic factors
associated with alleles of the major histocompatibility complex (MHC) as well as
environmental factors. The development of seropositive, but not seronegative RA is
associated with the presence in an individual of the HLA alloantigen HLA-DR4. A lot
of genetic aspects of RA has been studied and is still under active investigation and
research (Al-Mughales, 2015).

1.4 Common Types of Arthritis
There are over hundred types of arthritis that can cause weakness, pain, and
life-difficulties. According to Arthritis Foundation, the most common types of arthritis
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that affect patient’s activity are osteoarthritis (OA), rheumatoid arthritis (RA),
psoriatic arthritis (PsA), lupus, and gout. The difference between RA and OA is the
nature of the disease (Freeman, 2018 ). RA is an autoimmune disease where joints and
sometimes other organs are attacked by an individual’s immune system, while OA is
a degenerative joint disorder that results in wear and tear of joints. OA is the most
common chronic condition of the joints that occurs when the cartilage between joints
starts to collapse. There are several factors that causes OA including genetic variations,
obesity, injuries, metabolic disorders as well as joint diseases such as RA. On the other
hand, the causes of RA are not fully understood. The reason for the sudden abnormal
response of the immune system to body-tissues is yet to be clearly elucidated.
However, it has been reported that hormones, environmental factors and genes are the
leading causes of RA. The symptoms of OA and RA are quite similar which confuses
patients and physicians. Based on the Arthritis Foundation, symptoms include joint
pain, swelling or stiffness, joint tenderness and fatigue particularly occurring in the
morning, and limited range of motions. Gout is a type of arthritis that causes
inflammation, usually in one joint, which begins suddenly. Gouty arthritis is caused
by the deposition of crystals of uric acid in a joint (Driver, 2019). Accordance to the
Lupus Foundation of America, lupus is considered as a type of arthritis since many
symptoms of arthritis are also present. Lupus is an autoimmune disease in which the
immune system is very active. A long-period of inflammation leads to uncontrolled
lupus or “lupus arthritis”. PsA is a form of arthritis which is developed by people with
psoriasis (Mayo Clinic, 2018). PsA is believed to be caused by genes or infections and
sometimes by other factors such as stress and injury. Symptoms of PsA include joint
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pain, stiffness, skin problems, eyes problems, changes in nail color and shape and
swelling in fingers and feet (Freeman, 2018 ).

1.5 Pathophysiology of RA
RA is one of the most prevalent forms of autoimmune arthritis that is
characterized by inflammation of the joint lining the synovium. Synovial joints
strengthen and support joints, including the cartilage, tendon, ligament, and muscle.
Each of these structures are made up of different kind of tissues, and these tissues are
made up of specialized cells (Figure 1) (Shlotzhauer et al., 2014). RA is a gradual
inflammatory syndrome characterized by proliferation of the synovial membrane and
constant uncontrolled inflammation resulting in chronic destructive polyarthritis
(Hoxha, 2018). In RA the immune system does not recognize the body’s tissue and
attacks it as if it was an invader. Subsequently, a cascade of immune reactions results
in inflammation, thickening of synovial lining, angiogenesis and cartilage destruction
(Brink et al., 2016; Yamamoto et al., 2015).

1.6 Autoimmune Response
The immune system is a complicated mechanism that enables the body to
defend itself against invaders. The production of autoantibodies against specific or
several self–antigens in the body is the hallmark of autoimmune disorders. The cause
of such antibodies production remains unclear. RA has been classified as an
autoimmune disease for nearly a century since the identification of RFs. RA is an
inflammation of the synovium, caused by an interaction between fibroblast-like

8
synoviocytes and cells of the innate immune system (Gierut et al., 2017). The function
of the innate immune system is to recruit immune cells to an infection site by producing
chemical factors like cytokines followed by an activation of a cascade of several
components of the immune system (Janeway et al., 2008).
40-65% of RA patients are seropositive and around 20% are seronegative. In
seropositive patients, blood tests show the presence of antibodies that attack the body
and lead to joints inflammation. Antibodies elevated in RA patients include RFs, anticitrullinated protein antibodies (ACPAs) or both (Nakken et al., 2017; Smolen et al.,
2016; Verheul et al., 2015).

Figure 1: Schematic view of a normal joint (a) and a joint affected by RA (b).
The joint affected by RA (b) shows increased inflammation and cellular activity
( Choy, 2012).
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1.7 Autoantibodies Associated with RA
Over the past 25 years, an abundance of autoantibodies has been associated
with RA and its activity. The discovery of these autoantibodies continue without
reaching a comprehensive idea about its association with the disease (Choy, 2012). RF
was an early autoantibody linked with RA that is present in about 75% of RA
seropositive patients. Anti-RA33 antibodies was found in 36% of RA sera while anticalpastain was found in about 45% of RA sera (Brink et al., 2016; Nakken et al., 2017;
Boekel et al., 2001; Verheul et al., 2015). Sa protein or citrullinated vimentin, was
present in about 40% of the RA sera with high specificity (Brink et al., 2016; Nakken
et al., 2017; Boekel et al., 2001; Verheul et al., 2015). Anti-citrullinated protein
antibodies (ACPAs) are early markers for RA that are detectable before the onset of
the clinical symptoms. ACPAs are the most specific autoantibodies used as RA
markers. The role of ACPAs in RA, however, has not been clearly established. ACPAs
are associated with the shared epitope (SE) (Figures 2 and 3) of HLA-DR1 and
generated via T-helper cell and B-helper cell. Heavy chain binding protein (p68) and
glucose-6-phosphate isomerase are also found in RA patients (Brink et al., 2016;
Holers, 2013; Nakken et al., 2017; Boekel et al., 2001; Woude & Catrina, 2015;
Verheul et al., 2015).
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antibody

epitope

antigen

Figure 2: Antigens are the molecules recognized by the immune response, while
epitopes are sites within antigens to which antigen receptors bind (Janeway et al.,
2008).

Figure 3: An antibody binds an antigen directly, whereas a T-cell receptor binds a
complex of antigen fragment and self-molecule (Janeway et al., 2008).

1.8 Genetic Association of RA
Both genetic and environmental factors play a role in RA. Genetic factors play
a strong role in RA progression and severity. Variations in several genes have been
studied as risk factors for RA. Most of these genes are known or believed to be
involved in immune system and forms part of the major histocompatibility complex
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(MHC) or specifically human leukocyte antigen (HLA) in humans (Firestein &
McInnes, 2017). It has been established that the most common components of HLA
class II such as HLA-DRB1 is involved in several autoimmune disease including type
1 diabetes, Graves’ disease and RA (Gough et al., 2007). Previous studies have
demonstrated that RA progression and severity is associated with HLA-DRB1
polymorphisms (Weyand et al., 2000; Barnetche et al., 2002).

1.9 Major Histocompatibility Complex (MHC)
MHC is a gene family that exists in many species. It consists of more than 200
genes. In humans, the MHC genes cluster on chromosome 6. The cytogenetic location
of MHC in human is on the short arm within 6p21.3 and spans around 4,000 kilobases
(Mizuki & Kimura, 1996). HLA is the human form of MHC. MHC encodes a set of
membrane glycoproteins called the MHC molecules. Genes in this complex are
categorized into three main groups: class I, class II, and class III (Genetics Home
Reference, 2009). The genes encoding the α chains of MHC class I molecules and the
α & β chains of MHC class II molecules are linked within the complex (Figure 4)
(Janeway et al., 1996). MHC class I proteins are found in all cells while MHC class II
proteins are found in phagocytes. T helper cells recognize antigen in association with
MHC II and T cytotoxic cells recognize antigen in association with MHC I (Janeway
et al., 2008). The figure below shows the relative position of MHC class I and class II
genes on the short arm of chromosome 6 at position 6p21.3 along with specific exons
within these gene with known variations associated with RA (Figure 5) (Warren et al.,
2012).
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Figure 4: The structure of an MHC class I molecule (Transplantation Immunology,
2015).

Figure 5: The relative position of the HLA genes on the short arm of chromosome 6
and the exons to be considered (Warren et al., 2012).

1.10 Class I MHC/HLA Genes
MHC I is made of an α chain (43 kDa) and small peptide called β2-
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macroglobulin (12 kDa). The extracellular domains show variability in their amino
acid sequences, resulting in grooves with different shapes (Figure 6). MHC I binds to
short peptides of 8-10 amino acid and T cytotoxic cells recognize antigen associated
with MHC I (Janeway et al., 2008).

Figure 6: The structure of an MHC class I molecule (Janeway et al., 2008)

In humans, there are three major loci that code for MHC I molecules (HLA-A,
HLA-B and HLA-C). Within a locus, there are different allelic forms of the molecules.
For example, HLA-A2 and HLA-Aw68 class I molecules differ from one another at
13 amino acid residues. These distinctions in allelic forms of HLA molecules results
in dramatic differences in the shape of the groove of the molecule, where foreign
peptides are accommodated. Each individual can express up to two types of HLA-A
alleles, one each inherited from a set of parents. Some individuals will inherit the same
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HLA allele from both parents that thereby decreasing the individual’s HLA diversity.
The MHC is polymorphic and exhibits codominant expression. Thus, most individuals
are likely to be heterozygous at each locus. Because the human population is
extensively outbred, the MHC genetics in humans is extremely complex (Figure 7)
(Janeway et al., 2008).

Figure 7: Expression of MHC alleles is codominant (Janeway et al., 2008).

1.11 Class II MHC/HLA Genes
The class II genes of MHC provides instructions for making proteins present
on the surface of certain immune system cells (Janeway et al., 1996). The genetic locus
encoding class II molecules is known as the D region in humans. The D region is
further subdivided into several groups. There are seven super types of class II HLA-D
genes (main DR, DR4, DRB3, main DQ, DQ7, main DP and DP2) (Greenbaum et al.,
2011). Like the HLA class I genes, HLA-D class II genes also exhibit polymorphism
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and codominant expression. MHC class II is always expressed by B lymphocytes and
dendritic cells. It is composed of an α chain (30-34 kDa) and a β chain (26-29 kDa).
In MHC class II, the extracellular domains show variability in their amino acid
sequences resulting in grooves with different shapes (Figure 8). The length of the
peptides bound is not constrained. It could be at least 13 amino acid long and can be
much longer. T helper cells recognize antigen in association with MHC II (Janeway et
al., 2008; Janeway et al., 1996). In plentiful numbers of individuals, HLA-DR cluster
consist of an additional β chain gene and its product can pair with the DRα chain (
Janeway et al., 1996; Scrivo et al., 2007).

Figure 8: The structure of an MHC class II molecule (Janeway et al., 2008).

1.12 Class III HLA Genes
Class III HLA genes encode complement components that show no structural
similarity to ether class I or class II molecules. MHC class III region resides between
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the MHC class I and class II regions (Wennerstrom et al., 2013). These genes, along
with genes encoding tumor necrosis factor (TNF), separate HLA class II and HLA
class I genes on chromosome 6 in humans (Figure 9) (Matzaraki et al., 2017).

Figure 9: The genetic organization of the major histocompatibility complex (MHC)
in human (Janeway et al., 2008).

1.13 MHC Functions and Pathways
The function of MHC is to bind to peptide fragments from infectious agent and
present them on the cell surface. Appropriate T cells can then recognize the infected
cell and destroy it. This mechanism obstructs pathogens from dodging the immune
system. Class I and class II of MHC molecules binds peptides to T cells, however,
each type has its own pathway for binding peptides (Figure 10) (Janeway et al., 2008;
Kobayashi & Elsen, 2012).
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Figure 10: The (a) MHC class I and (b) MHC class II antigen-presentation pathway
(Kobayashi & Elsen, 2012).

1.14 Nomenclature and HLA Classifications
HLA started as a list of antigens identified because of transplant rejections (Ka
et al., 2017; Thorsby, 2009). The antigens were initially identified by massive
statistical analysis of the interactions between blood types. This operation is in
accordance with the principle of serotypes. HLA genes of the host consists of different
antigens from those found on the surface of infectious agents. HLAs are alloantigen,
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which are responsible for binding to non-self-antigens from member of the same
species. In another word, the alloantigen is present only in some, but not all, members
of a species and it stimulates the production of alloantibody by individuals lacking that
antigen in grafting and organ transplants or even in blood group. This determines the
acceptances or rejection of the organs and blood between individuals (Janeway et al.,
2008). HLA vary between individuals due to genetic differences. One of the most
complex regions of the human genome is the HLA locus. In spite of the fact that it
represents only 0.3% of human genome, it constitutes 1.5% of genes in OMIM, and
6.4% of SNPs in the genome are based in this region (Ka et al., 2017; Thorsby, 2009).
Many different versions or alleles of HLA genes have been identified by researchers.
Each allele is assigned a specific notation. The most recent HLA naming system was
developed in 2010 by the WHO Committee for Factors of the HLA System. They
developed a systematic naming convention for identifying the variations in HLA
alleles. There are two types of MHCs, Class I and Class II MHCs are named with the
same system. Alleles that started with “HLA” represent the human MHC genes. The
next part (HLA-A or HLA-B) identifies which gene the allele is a modification of.
Each HLA allele has a unique number that consists of four set of digits separated by
colons. The digits before the colon represents the type that is associated with the
serological antigen supported by an allotype, the allele of the antibody chains found in
the individual. The digits after the colon is used to list the subtypes of the DNA
sequences that have been identified. For example, in HLA-DRB1*04, the HLA is a
prefix, DRB1 is the gene followed by a separator and 04 is the allele group. Sometimes
four digits follow, for example HLA-DRB1*04:01, in which case 01 is a specific HLA
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protein. The third group of digits, for example 02 in HLA-DRB1*04:01:02, refer to
allele variants which produce same protein. The fourth set of digits are used for noncoding region of the gene (Figure 11,12). The final aspect of HLA naming is a letter
used to denote changes in expression. There are six letters, each with a different
meaning (Table 1) (Marsh & System, 2011; Scally et al., 2013).

Figure 11: Interpretation of digits in HLA genes (Marsh & System, 2011).

Figure 12: Nomenclature of HLA Alleles.
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Table 1: The final aspect of HLA naming
Letter

Significance

N

Null Allele (Presents a non-functional protein)

L

Lower than normal cell surface expression

S

Soluble protein absent from the cell surface

Q

Questionable (allele may affect the expression)

C

Protein is found in cytoplasm and absent on cell surface

A

Aberrant or irregular expression

1.15 Association of HLA Genes with RA
The inheritance pattern of RA is unclear due to the involvement of numerous
genetic and environmental factors. The HLA loci have been identified as the genes
most associated with RA (Kochi et al., 2014; Viatte et al., 2015; Weyand et al., 2000).
Several allelic variants of HLA gene have been associated with RA. Studies have
indicated that RA is associated primarily with HLA-DRB1 alleles, especially 'HLADRB1*04' allele. HLA-DR is a cell surface receptor that provides information to make
protein functions in immune system response. It provides instructions to present
peptide antigens to the immune system to elicit or suppress T-helper cell responses
(Janeway et al., 2008; Ruyssen-Witrand et al., 2015; Scally et al., 2013; Viatte et al.,
2015; Wennerström et al., 2013). The association of the HLA-DRB1 with RA is
strongly associated with conserved sequences at amino acid positions 70-74 in the
protein referred to as the shared epitope (SE) (Ruyssen-Witrand et al., 2015; Scally et
al., 2013). This conserved region with the sequence QKRAA/QRRAA/RRRAA,
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which involves alleles HLA-DRB1*01:01, HLA-DRB1*04:01, HLA-DRB1*04:04,
HLA-DRB1*10:01, have been strongly associated with RA (Ruyssen-Witrand et al.,
2015). Additional classifications of HLA-DRB1 associated with RA has expanded this
to the presence of an aspartic acid 'D' at position 70 and the DERAA SE motif between
positions 70-74. Further, it has been demonstrated that the amino acid at position 11
and 13 also increases the risk of RA (Ruyssen-Witrand et al., 2015). The presence of
Val11 in HLA-DRB1 has been reported to be strongly associated with seropositive
RA, while the amino acids most associated with seronegative RA is HLA-DRB1 were
Ser11 and Leu11 and the allele type HLA-DRB1*03. It has also been shown that HLAA Asn77 is also significantly associated with seropositive RA (Figure 13) (Han et al.,
2014).

Figure 13: 3D models of HLA proteins with amino acid positions that are
significantly associated with RA (Han et al., 2014).
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Figure 14: 3D models of HLA proteins with additional amino acid positions that are
known to be associated with RA (Raychaudhuri et al., 2012).

Furthermore, three additional positions in HLA-DRB1 - His13, Lys71, and
Ala74 - and single amino acid polymorphism in HLA-B - Asp9 - and HLA-DP1 - Phe9
– were associated with an increased risks of seropositive RA (Figure14) (Greenbaum
et al., 2011; Raychaudhuri et al., 2012).
It was reported that in Black Sea Turkish population, the frequency of HLADRB1*01, *04, and *09 alleles are higher in RA patients and the conserved SE at
position 70-74 is commonly QKRRA (Uçar et al., 2012). In African Americans
population, a Val11 variation, corresponding to allele *09:01, was observed to impart
high RA risk, which was also the same allele for RA in the Korean population. A recent
study established that in European ancestry, HLA-DRB1*04:01, *04:04, and *01:01
are the most frequent RA risk alleles, whereas in East Asian populations, HLADRB1*04:05 and *01:01 were the most frequent RA risk alleles (Yamamoto et al.,
2015). In addition, several subtypes of the DR4 allele, such as *04:02 and *04:03
appear to confer protection against the disease (Yamamoto et al., 2015). The protective
effects of DRB1 allele, DRB1*13:02, in Japanese RA has also been reported (Oka et
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al., 2014). A study involving the typing of HLA-DRB1 in Saudi Arabian RA patients
found that HLA-DRB1*04 followed by HLA-DRB1*08 and HLA-DRB1*10 are
alleles that could be used as predictors for RA. Additionally, the frequency of HLADRB1*06 was observed to be lower in RA compared to control (Al-Swailem et al.,
2006). Table 2 provides a summary of HLA-DRB1 alleles that have been reported to
be associated with RA in various populations.

Table 2: Distribution of HLA-DRB1 alleles and genotypes frequencies in RA among
different population.
Population

HLA-DRB1 allele
*04

*09:01

*15

Japanese
African American

*09:01

Reference
(Al-Swailem et al., 2006;
Oka et al., 2014; Shimane
et al., 2013)
(Reynolds et al., 2014)
(Al-Swailem et al., 2006;
Reynolds et al., 2014)

*09:01

*04:05

European

*01:01

*04:01

*04:04

(Reynolds et al., 2014)

Turkish

*01

*04

*09

(Uçar et al., 2012)

Saudi

*01

*04

*08

(Al-Swailem et al., 2006)

French

*01

(Uçar et al., 2012)

Latin Americans

*01

(Uçar et al., 2012)
(Uçar et al., 2012;
Yamamoto et al., 2015)

Korean

*01

*04:05

Caucasians

*01

*09

Chileans

*09

Syrian

*01:01

Asians

(Uçar et al., 2012)
(Uçar et al., 2012)

*04:04

*04:05

(Saxena et al., 2017)
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1.16 RA in United Arab Emirates
Over 20% of UAE’s population suffer from at least one type of arthritis
(Carmona et al., 2002). RA is the most common inflammatory arthritis (Drongelen &
Holoshitz, 2017). In UAE, RA is widespread with delayed diagnosis. Dubai Bone and
Joint Center classifies patients with RA by the symptoms and their ages. Only
individuals who are 16 and above and have RA symptoms are categorized as RA
patients (Badsha et al., 2008). Additionally, more females were diagnosed with RA
than males (Badsha et al., 2008; Saxena et al., 2017). A recent study evaluated the
factors causing RA in Arab populations. RA patients from Jordan, the Kingdom of
Saudi Arabia, Lebanon, Qatar, and the United Arab Emiratis were examined to check
the genetics and clinical features of the disease. The study concluded that HLA-DRB1
amino acid position 11 was strongly associated with seropositive RA in Arabs (Saxena
et al., 2017).

1.17 Whatman FTA Technology
Flinders Technology Associates (FTA), or now Whatman FTA Card, is a filter
paper based system manufactured by GE Health Care that provides a safe and reliable
technique for storage of DNA at the room temperature for several years (Ndunguru et
al., 2005). It has been reported by the manufacturers that DNA remains stable for at
least 17 years or more. As proof, researchers were able to generate short tandem repeat
(STR) data with good signal strength from DNA from 22-years-old blood (Mullen et
al., 2009; Whatman FTA Technology). The FTA card is a special type of filter paper
(Figure 15A) which consist of two types of reagents – one that regulate cell lysis and
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protein denaturation and the other that protect DNA from denaturation (Entezami et
al., 2011; Santos, 2018). Different kind of samples (blood, bacteria, buccal cells,
cultured cells, plant material, and more) can be applied either directly or with a swab
to FTA cards (Whatman). The cards are white, pink, or purple color. Pink and purple
include a dye which turns white when colorless samples are applied (Figure 15B)
(Whatman FTA Technology). FTA technology is widely for human DNA collection,
archiving of nucleic acids for forensic applications and PCR-based genotyping
(Ndunguru et al., 2005). After drying the sample, a small disc from the card is removed
using a puncher to recover nucleic acids. The discs are washed with FTA reagents, and
can be directly used for amplification by PCR. Since FTA cards require only a few
drops of blood, which could significantly reduce the trauma associated with blood
collection especially in children, as well as reduce the chance of infection, this study
decided to investigate FTA cards as a means of collecting and extracting DNA for
routine testing.
A

B

Figure 15: (A) Whatman FTA cards (B) FTA card that turns white when colorless
samples are loaded (Avantor; Cole-Parmer Canada Company).
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1.18 Hypothesis
The HLA loci have been established as a strong risk factor associated with RA.
Specifically, the SE region of HLA-DRB1 has been documented as the strongest
indicator. Additionally, other variations at position 11 and 13 of HLA-DRB1 and
position 77 of HLA-A are also very good risk factors. The hypothesis of this study was
that these variations could be observed in RA patients in the UAE.

1.20 Objective of the Study
The main aim of this study was to understand the variation of HLA genes
in RA patients from Fujairah Hospital in UAE. Identification of variations in HLA
alleles could help in understanding the possible genetic cause of RA in this region
which could further be expanded to the population of UAE at a later stage. Specifically,
this would involve identifying the variations in the genes HLA-A from class I of MHC
and HLA-DRB1 from class II of MHC, which are two genes that harbor variations
associated with RA. Blood samples were collected and loaded on Whatman FTA card
and exon 2 and 3 of HLA-A and exon 2 of HLA-DRB1 would then be amplified using
polymerase chain reaction (PCR) and sequenced to compute the incidence of the
known variants associated with RA.
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Chapter 2: Methods

2.1 Ethical Approval
Ethical approval was obtained from the Center of Research and Statistics,
Ministry of Health and Prevention (MOHAP) to collect samples from Fujairah
Hospital. Ethical approval no: MOHAP /DXB-REC-SUB-30/2017, was granted on 23
August 2017 and renewed on 10 December 2018 up to 9 December 2019.

2.2 Patients and Controls
To be eligible for the study, patients had to be Emirati, should have been
clinically diagnosed with RA, be at least ≥ 18 years of age, and be able to sign an
informed consent. Healthy controls included individuals who had not shown any
clinical symptoms of RA. A total of 54 RA patient samples and 44 healthy control
samples were analyzed in this study. Subjects were enrolled from Fujairah Hospital
during the period 25 August 2017 to March 2018.

2.3 Sample Collection
2 ml of whole blood was collected from patients and controls by venipuncture
into vacuum collection tubes containing dipotassium EDTA (Ethylene Diamine
Acetate). One drop (around 50 μl) was applied to a Whatman™ FTA Micro Card (Fig
16). Cards were dried at room temperature, transported to Department of Biology,
United Arab Emirates University, for further analysis.
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Figure 16: FTA card spotted with human whole blood.

2.4 Storage Condition
Whatman™ FTA cards that contained blood samples were stored at room
temperature in a safe cabinet at UAE University with coded numbers. Original blood
samples collected in EDTA tubes were stored at -50°C in a safe room at Fujairah
Hospital.

2.5 DNA Extraction
FTA cards that contained blood samples were punched twice using Harris®
Uni-CoreTM 1.2 mm puncher (Figure 17) and placed in a PCR tube for washing. To
avoid cross contamination between samples, an equivalent number of discs were taken
from a blank FTA cards after each sample. The two small punched discs were washed
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for 45 minutes in 200 µl of Whatman FTA purification reagent. The discs were then
washed for 10 minutes in 200 µl of 1 mM TE buffer. The washed discs were left to
dry at room temperature for up to 30 minutes. The two washed discs were then used
for PCR. Using FTA card for PCR does not require DNA extraction or quantification
since the amount of DNA in the disc is sufficient for PCR .

Figure 17: Harris® Uni-CoreTM 1.2 mm puncher.

2.6 Primers
The sequence of HLA-DRB1 gene and HLA-A gene were retrieved from
Ensemble genome browser. The sequences were further cross checked with the
sequence obtained from National Center for Biotechnology Information (NCBI)
database. The coding exons 2 and 3 were marked and primers were designed that
covered this region. Melting temperature and GC content of each primer were also
calculated. Designed primers were purchased from Macrogen (Korea). The optimum
conditions for the primers were then determined experimentally using multiple PCR
test runs. The list of primers and their optimal conditions are given in Table 3.
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Table 3: Primers set used in PCR to amplify different HLA genes.

Gene

Forward Primer

HLA-DRB1 5’- GATGGTGGCGTCGCTGTC-3’

Annealing

Annealing

Temperature

Time

(°C)

(sec)

5’-GCTCTCAGAACTGCTTGCT-3’

59

35

Reverse Primer

(exon 2)

5’-GAAGACGGAGGATGAGCTCC-3’

5’-GAACTGCTTGCTCCGGACTG-3’

59

35

HLA-A

5’-TTGGGTGTCGGGTTTCCAGAGA-3’

5’-CTCTCCCGGGACAAGGGTCTC-3’

66

40

(exon 2)

5’-TCGTCGCGGTCGCTGTTCTA-3’

5’-CTTCGGGGTGGATCTCGGACC-3’

66

40

HLA-A

5'-GAGACCCTTGTCCCGGGAGAG-3'

5'-GTCAGAGAGCAGGGCGGAACC-3'

67

40

(exon 3)

5'-CAGGAGACACGGAATGTGAAG-3'

5'-CAATTGTCTCCCCTCCTTGTG-3'

61

35
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2.7 PCR amplification
The Go Taq® Green Master Mix (Promega, USA), which is a premixed readyto-use solution, was used in this study. Go Taq® Green Master Mix contains Taq DNA
polymerase, dNTPs, MgCl2 and reaction buffers at optimal concentrations. A reaction
volume of 50 µl was used for each PCR run. Two FTA discs were added to each PCR
tube. The reaction conditions used in the Thermal Cycler (Figure18) were as follows:
1 cycle at 95ºC for 3 minutes followed by 34 cycles of denaturation at 95ºC for 30
seconds, annealing at temperature and time provided in Table 3, and finally extension
at 72ºC for one minute. Amplified products were visualized on 1.5% (w/v) agarose gel
using electrophoresis.

Figure 18: BioRad T100™ Thermal Cycler.
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2.8 Gel Electrophoresis
1.5% (w/v) agarose CSL-AG500 (Cleaver Scientific) gel was prepared using
0.75 grams of agarose in 50 ml of 1 X Tris-Borate EDTA (TBE) buffer (0.89 M Trisborate, 0.032 M EDTA, pH 8.3) and heated in a microwave for 1-2 minutes until it
dissolved completely. The gel mixture was cooled to room temperature and 2 µl of
ethidium bromide was added. When the gel had cooled adequately, it was poured into
a gel tray. Once the gel solidified, 5 µl of 100 bp DNA ladder (N3231S-BioLabThermoFisher) was added followed by PCR products which were added immediately
into wells without using a loading dye. The Go Taq® Green Master Mix used includes
two dyes that allowed the monitoring of the progress of electrophoresis. Bio Rad
PowerPac™ Basic machine was used for electrophoresis. The voltage and current were
set at 120 V and 400 A, respectively, and the gel was allowed to run for 20 minutes. It
was subsequently visualized and recorded using a Compact Digimage System, UVDI
series gel documentation system.

2.9 Purification of PCR products
The amplified PCR products were purified using the Norgen PCR purification
kit (Norgen Biotek, Canada). For this purpose, the binding buffer provided in the kit
was added in 5:1 ratio to the PCR product. This was vortexed and pulse-spun briefly.
The mixture was then transferred into a column provided in the kit and centrifuged for
1 minute at 8000 rpm. The flow-through was discarded and 500 µl of washing buffer
(96-100% ethanol) was added to the column and centrifuged for 1 minute at 10,000
rpm. The flow-through was discarded again and the spun for 2 minutes at 14,000 rpm
in order to dry the column. The column was then assembled with the provided 1.7 mL
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elution tube. To increase DNA concentration 10 µl of elution buffer was added to the
center of the column bed and kept standing at room temperature for 1 minute. The
column was then centrifuged for 2 minute at 14,000 rpm. The last step was repeated
once more. Quantity and quality of the purified DNA was evaluated by loading 1µl of
purified DNA in NanoDrop 2000/c (Thermo Fisher Scientific, USA) which is a
microvolume spectrophotometers.

2.10 DNA Sequencing
Samples that satisfied the required quality and quantity were sent to Macrogen,
(Korea) for sequencing. The sequences and chromatograms were provided by
Macrogen which were then analyzed further.

2.11 Analysis of Sequencing Data
FinchTV chromatogram viewer version 1.4.0 (Geospiza) was used to visualize
the chromatograms. BioEdit Sequence Alignment Editor Version v7.0.5 (Tom Hall
Ibis Therapeutics) and JalView (Waterhouse et al., 2009) were used to perform
sequence alignment. Reference sequences for HLA-DRB1 (NCBI Accession:
NG_029217) and HLA-A (NCBI Accession: NG_029921) were obtained from NCBI
RefSeq database. Phylogenetic trees were generated using MEGA 6 (Kumar et al.,
2016) using the Maximum Likelihood algorithm (Kumar et al., 2016).

2.12 HLA Allele Type Determination
A custom BLAST server containing all known HLA sequences obtained from
HLA Nomenclature (http://hla.alleles.org) (Figure 19) was used for HLA allele
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determination. Following the convention, for the class I gene, HLA-A, sequences of
exons 2 and 3 were combined for allele type determination. For the class II gene, HLA
DRB1, sequence of exon 2 was used for allele type determination using BLAST. HLA
allele type frequencies were then computed.

Figure 19: A custom BLAST server (http://compbio.uaeu.ac.ae/blast-hla) to search
HLA sequences obtained from HLA Nomenclature (http://hla.alleles.org)

2.13 Homology Modeling
To locate the spatial orientation of the variations with higher incidence in
patients, homology models of the mutant HLA proteins were generated using the
online SWISSMODEL server (https://swissmodel.expasy.org/). The obtained models
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were visualized in VMD 1.9.2 (Humphrey et al., 1996) and the Schrodinger Suite
2018-1 (Schrödinger, 2018).

2.14 Statistical Analysis
For computation of odds ratio for specific variations, Fisher’s exact test was
performed in R after generating contingency tables. To identify if there are genetic
differences between patient and control groups, Fixation Index (FST) was computed
using Arlequin 3.5.2 (Excoffier & Lischer, 2010). To identify if some or all of the
patient and control samples cluster separately, Principal Component Analysis (PCA)
was performed using aligned DNA sequences. The adegenet library was employed in
R version 3.6.0 for performing PCA and plotting the principal components.

36

Chapter 3: Results

3.1 HLA Gene PCR Amplification
PCR was used to amplify genomic region encompassing exon 2 of HLA-DRB1
and exons 2 and exon 3 of HLA-A. These are regions essential for HLA typing and
also known to harbor variations strongly associated with RA. Figures 20, 21 and 22
are sample gel electrophoresis images that shows bands of the expected size. HLADRB1 exon 2 amplicon has size 529 bp, HLA-A exon 2 is 705 bp, and HLA-A exon
3 is 598 bp. These samples were then purified and sent for DNA sequencing using the
same primers used for PCR.

Figure 20: Gel electrophoresis image of PCR products of HLA-DRB1 exon 2.

Figure 21: Gel electrophoresis image of PCR products of HLA-A exon 2.
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Figure 22: Gel electrophoresis image of PCR products of HLA-A exon 3.

Chromatograms obtained from sequencing were inspected using Finch TV
Viewer (Figure 23) and the sequences were aligned using BioEdit Sequence Alignmen
Editor and JalView (Waterhouse et al., 2009) to identify locations that harbor
variations (Figures 24-26).

Figure 23: Chromatogram of an HLA-DRB1 sample visualized in FinchTV viewer.
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Figure 24: Sequence alignment of sample HLA-DRB1 exon 2 sequence with the reference HLA-DRB1 sequence obtained from NCBI
(NG_029921). Sequence alignment was performed in JalView (Waterhouse et al., 2009).
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Figure 24: Sequence alignment of sample HLA-DRB1 exon 2 sequence with the reference HLA-DRB1 sequence obtained from NCBI
(NG_029921). Sequence alignment was performed in JalView (Waterhouse et al., 2009) (Continued).
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Figure 24: Sequence alignment of sample HLA-DRB1 exon 2 sequence with the reference HLA-DRB1 sequence obtained from NCBI
(NG_029921). Sequence alignment was performed in JalView (Waterhouse et al., 2009) (Continued).
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Figure 24: Sequence alignment of sample HLA-DRB1 exon 2 sequence with the reference HLA-DRB1 sequence obtained from NCBI
(NG_029921). Sequence alignment was performed in JalView (Waterhouse et al., 2009) (Continued).
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Figure 25: Sequence alignment of sample HLA-A exon 2 sequences with the reference HLA-A sequence obtained from NCBI
(NG_029217). Sequence alignment was performed in JalView (Waterhouse et al., 2009).
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Figure 25: Sequence alignment of sample HLA-A exon 2 sequences with the reference HLA-A sequence obtained from NCBI
(NG_029217). Sequence alignment was performed in JalView (Waterhouse et al., 2009) (Continued).
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Figure 26: Sequence alignment of sample HLA-A exon 3 sequences with the reference HLA-A sequence obtained from NCBI
(NG_029217). Sequence alignment was performed in JalView (Waterhouse et al., 2009).
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Figure 26: Sequence alignment of sample HLA-A exon 3 sequences with the reference HLA-A sequence obtained from NCBI
(NG_029217). Sequence alignment was performed in JalView (Waterhouse et al., 2009) (Continued).
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3.2 HLA-DRB1 Allele Typing
Allele typing of a HLA class II gene like HLA-DRB1 is normally performed
with the sequence of exon 2. The exon 2 sequence of HLA-DRB1 was used as the
input to perform a BLAST search against the HLA allele database deployed in a
custom BLAST server in the lab (http://copbio.uae.ac.ae/blast-hla/). BLAST results
were interpreted to identify the HLA-DRB1 allele type up to 4-digit resolution for
control and patient samples. Allele types determined for controls are listed in Table 4
and a summary of the incidence of each allele type is provided in Table 5, while the
allele types determined for patients are listed in Table 6 and the corresponding
summary in Table 7.
Table 4: HLA-DRB1 allele type in control (C) samples.
Sample
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20

Allele
DRB1*16:01
DRB1*16:02
DRB1*16:02
DRB1*16:01
DRB1*16:01
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*15:02
DRB1*16:02
DRB1*16:02
DRB1*16:01
DRB1*16:02
DRB1*16:02
DRB1*16:02
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Table 4: HLA-DRB1 allele type in control (C) samples (continued).
Sample
C21
C22
C23
C24
C25
C26
C27
C28
C29
C30
C31
C32
C33
C34
C35
C36
C37
C38
C39
C40
C41
C42
C43

Allele
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:01
DRB1*16:02
DRB1*15:03
DRB1*16:01
DRB1*15:03
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:01
DRB1*16:01
DRB1*15:02
DRB1*16:02
DRB1*16:02

Table 5: Summary of HLA-DRB1 allele types in control samples at 4-digit and 2digit resolutions.
Allele

Count (4-digits)

DRB1*15:02

2

DRB1*15:03

2

DRB1*16:01

8

DRB1*16:02

31

Total

43

Count (2-digits)
4

39
43
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Tables 4 and 5 show that the most frequent HLA-DRB1 allele in control samples is
DRB1*16. It was found in 39 samples out of 43 while the DRB1*15 allele comes
next with 4 samples out of 43.

Table 6: HLA-DRB1 allele types in patient (RA) samples.
Sample
RA1
RA2
RA3
RA4
RA5
RA6
RA7
RA8
RA9
RA10
RA11
RA12
RA13
RA14
RA15
RA16
RA17
RA18
RA19
RA20
RA21
RA22
RA23
RA24
RA25
RA26
RA27
RA28
RA29
RA30
RA31

Allele
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*15:01
DRB1*10:01
DRB1*15:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*15:02
DRB1*01:02
DRB1*16:01
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:01
DRB1*15:01
DRB1*16:01
DRB1*15:02
DRB1*15:01
DRB1*15:02
DRB1*15:01
DRB1*16:01
DRB1*15:02
DRB1*15:01
DRB1*15:02
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Table 6: HLA-DRB1 allele types in patient (RA) samples (continued).
Sample
RA32
RA33
RA34
RA35
RA36
RA37
RA38
RA39
RA40
RA41
RA42
RA43
RA44
RA45
RA46
RA47
RA48
RA49
RA50
RA51
RA52
RA53
RA54

Allele
DRB1*16:01
DRB1*16:01
DRB1*15:02
DRB1*16:01
DRB1*15:114
DRB1*16:02
DRB1*16:01
DRB1*16:01
DRB1*15:02
DRB1*16:01
DRB1*16:02
DRB1*16:02
DRB1*16:02
DRB1*16:01
DRB1*16:02
DRB1*15:01
DRB1*16:02
DRB1*16:01
DRB1*16:01
DRB1*16:01
DRB1*16:01
DRB1*16:01
DRB1*16:01

Table 7: Summary of HLA-DRB1 allele types in RA samples at 4-digit and 2-digit
resolutions.
Allele

Count (4-digits)

DRB1*01:02

1

Count (2-digits)
1

DRB1*10:01

1

1

DRB1*15:01

6

DRB1*15:02

8

DRB1*15:114

1

DRB1*16:01

17

DRB1*16:02
Total

20
54

15

37
54
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Interestingly, the DRB1*16 allele was the most abundant allele in patients. The high
risk alleles type such as DRB1*01 and DRB1*10 were found only is 3 RA samples.

3.3 Sequence of Shared Epitope and Other Regions of HLA-DRB1 Associated
with RA
The shared epitope region, which forms amino acids 70-74 of the mature
protein, is by far regarded as the strongest indicator of an association between HLA
genes and RA (Ruyssen-Witrand et al., 2015). From the sequence alignment and
translation from this, the SE region and the corresponding amino acids representing
this region are provided in Table 8 for controls and a summary of unique SE sequences
observed is provided in Table 9. SE sequences for patients are provided in Table 10
and the corresponding summary in Table 11. Outside the SE regions, variations at
positions 11 and 13 of the mature HLA-DRB1 protein are also known to be associated
with RA. The corresponding sequences observed in these samples are also listed in the
tables mentioned above. The sequence DRRAA was the most common SE in controls
(34/43) as well as patients (35/54). The QARAA was also present in a number of
patient samples (10/54), while the other observed SE sequences had low incidence in
these samples.
Table 8: HLA-DRB1 Shared epitope and positions 11/13 in control samples.

Sample

Shared Epitope (DNA)

C1
C2
C3
C4
C5

GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG

SE(7074)
Amino
acids
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA

Codons 11-13 (DNA)

Amino
acids
11-13

CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG

P-R
P-R
P-R
P-R
P-R
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Table 8: HLA-DRB1 Shared epitope and positions 11/13 in control samples.
(Continued)
Sample

Shared Epitope (DNA)

C6
C7
C8
C9
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C27
C28
C29
C30
C31
C32
C33
C34
C35
C36
C37
C38
C39
C40
C41
C42
C43

CACGGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACGAGCGGGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAAGCCCGCCCCG
GACAGGCGCGCCGCG
CACGCGCGCGCCGCG
GACAGGCGCGCCGCG
CAGGCGCGGGCCGCG
GACAGGCGCGCCGCG
CAGGCGCGGGCCGCG
GACAGGCGCGCCGCG
CACGGGCGCGCCGCG
GACGGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
CACGAGCGGGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG

SE(70-74)
Amino
acids
HGRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DERAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DKPAP
DRRAA
HARAA
DRRAA
QARAA
DRRAA
QARAA
DRRAA
HGRAA
DGRAA
DRRAA
DRRAA
HERAA
DRRAA
DRRAA

Codons 11-13
(DNA)
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
NOT AVAILABLE
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAAG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAAG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG

Amino
acids
11-13
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-K
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R

52
Table 9: Count of shared epitope sequence in control samples.
Shared epitope sequence

Count

DRRAA
HGRAA
DERAA
DKPAP
HARAA
QARAA
DGRAA
HERAA
Total

34
2
1
1
1
2
1
1
43

The low risk SE sequence DRRAA is more frequent in control samples which
is related to HLA-DRB1*16 allele type. The amino acid at position 11 and 13 did not
the high risk variant in the control samples.
Table 10: HLA-DRB1 Shared epitope and positions 11/13 in RA samples.

Sample

Shared Epitope (DNA)

SE(70-74)
Amino acids

RA1
RA2
RA3
RA4
RA5
RA6
RA7
RA8
RA9
RA10
RA11
RA12
RA13
RA14
RA15
RA16
RA17
RA18

GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
CACGGGCGCGCCGCG
CAGGCGCGGGCCGCG
CAGGCGCGGGCCGCG
CGGAGGCGTGCCGCG
CACGCGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
CACGCGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
CAGGCGCGGGCCGCG
CAGAGGCGGGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
CAGAGGCGGGCCGCG

DRRAA
DRRAA
HGRAA
QARAA
QARAA
RRRAA
HARAA
DRRAA
DRRAA
HARAA
DRRAA
DRRAA
DRRAA
QARAA
QRRAA
DRRAA
DRRAA
QRRAA

Codons 11-13
(DNA)
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
GTTAAGTTT
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CTTAAGTTT
CCTAAGAGG
CCTAAGAGG
CTTAGGTTT

Amino
acids
11-13
P-R
P-R
P-R
P-R
P-R
V-F
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
L-F
P-R
P-R
L-F
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Table 10: HLA-DRB1 Shared epitope and positions 11/13 in RA samples.
(Continued)
Sample

Shared Epitope (DNA)

SE(70-74)
Amino acids

Codons 11-13
(DNA)

RA19
RA20
RA21
RA22
RA23
RA24
RA25
RA26
RA27
RA28
RA29
RA30
RA31
RA32
RA33
RA34
RA35
RA36
RA37
RA38
RA39
RA40
RA41
RA42
RA43
RA44
RA45
RA46
RA47
RA48
RA49
RA50
RA51
RA52
RA53
RA54

GACAGGCGCGCCGCG
CAGGCGCGGGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
CACGCGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
CAGGCGCGGGCCGCG
GACAGGCGCGCCGCG
CACGAGCGGGCCGCG
CAGGCGCGGGCCGCG
CAGGCGCGGGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
CAGGCGCGGGCCGCG
GACAGGCGCGCCGC
CAGGCGCGGGCCGC
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
CACGCGCGGGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
CAGGCGCGGGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG
GACAGGCGCGCCGCG

DRRAA
QARAA
DRRAA
DRRAA
HARAA
DRRAA
DRRAA
DRRAA
QARAA
DRRAA
HERAA
QARAA
QARAA
DRRAA
DRRAA
QARAA
DRRAA
QARAA
DRRAA
DRRAA
DRRAA
HARAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
QARAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA
DRRAA

CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG
CCTAAGAGG

Amino
acids
11-13
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
P-R
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Table 11: Count of shared epitope in RA samples.
Shared epitope sequence
DRRAA
HGRAA
QARAA
RRRAA
HARAA
QRRAA
HERAA
Total

Count
35
1
10
1
4
2
1
54

In RA patients, the high risk SE sequences (RRRAA and QRRAA) were
observed only in the 3 sample out of 54 which belong to the high risk allele type of
HLA-DRB1 mentioned in Tables 6 and 7.

3.4 HLA-A Allele Typing
Unlike HLA-DRB1, a class II gene, allele typing of a HLA class I gene like
HLA-A is normally performed with the sequence of exon 2 and 3. For this, the
combined sequence of exon 2 and 3 of HLA-A was used as the input to perform a
BLAST search against the HLA allele database. BLAST results were interpreted to
identify the HLA-A allele type for control and patient samples. Allele types
determined for controls are listed in Table 12 and a summary of the incidence of each
allele type is provided in Table 13, while the allele types determined for patients are
listed in Table 14 and the corresponding summary in Table 15. At 2-digit resolution
the allele HLA-A*11 was the most common allele type observed in the controls
(14/44) and patients (21/38). Specifically, the HLA-A*11:88 had the highest incidence
of 15/38 among patients.
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Table 12: HLA-A allele type in control samples.
Sample
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C27
C28
C29
C30
C31
C32
C33
C34
C35
C36
C37
C38
C39
C40
C41
C42
C43
C44

Allele
A*31:110
A*31:08
A*31:10
A*11:88
A*34:03
A*11:40
A*11:88
A*32:15
A*32:01
A*33:119
A*01:244
A*26:70
A*03:10/A*33:150/A*68:129
A*11:40
A*03:22
A*29:02/A*33:18
A*01:200
A*11:17
A*31:111/A*33:9
A*33:59
A*33:18
A*33:13
A*02:97
A*30:117
A*33:85
A*11:88
A*30:26
A*30:09
A*26:70
A*03:57
A*23:70
A*11:40
A*11:40
A*26:172
A*03:78
A*11:26
A*11:99
A*03:343
A*03:343
A*01:136
A*11:33
A*11:199
A*11:99
A*11:99
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Table 13: Summary of HLA-A allele types in control samples at 4- and 2-digit
resolutions.
Allele
A*01:136
A*01:200
A*01:244
A*02:97
A*03:22
A*03:343
A*03:57
A*03:78
A*11:17
A*11:26
A*11:33
A*11:40
A*11:88
A*11:99
A*11:199
A*23:70
A*26:70
A*26:172
A*30:09
A*30:26
A*30:117
A*31:08
A*31:10
A*31:110
A*32:01
A*32:15
A*33:13
A*33:18
A*33:59
A*33:85
A*33:119
A*34:03
A*03:10/A*33:150/A*68:129
A*29:02/A*33:18
A*31:111/A*33:9
Total

Count (4 digits)
1
1
1
1
1
2
1
1
1
1
1
4
3
3
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
44

Count (2 digits)
3
1
5

14

1
3
3

3
2

5
1
1
1
1
1
44
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Table 14: HLA-A allele type in RA samples.
Sample
RA1
RA2
RA3
RA4
RA5
RA6
RA7
RA8
RA9
RA10
RA11
RA12
RA13
RA14
RA15
RA16
RA17
RA18
RA19
RA20
RA21
RA22
RA23
RA24
RA25
RA26
RA27
RA28
RA29
RA30
RA31
RA32
RA33
RA34
RA35
RA36
RA37
RA38

Allele
A*03:89
A*11:88
A*11:88
A*11:88
A*01:136
A*11:88
A*11:88
A*11:88
A*11:40
A*11:88
A*11:88
A*03:56
A*74:34
A*74:34
A*31:21
A*03:280
A*24:87
A*26:19
A*11:88
A*01:192
A*74:34
A*11:88
A*11:88
A*11:199
A*11:178
A*11:40
A*74:10
A*11:88
A*30:12
A*11:99
A*11:88
A*11:88
A*11:199
A*11:88
A*31:79
A*03:267
A*03:72
A*01:192
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Table 15: Summary of HLA-A allele types in RA samples at 4- and 2-digit
resolutions.
Allele

Count (4 digits)

Count (2 digits)

A*01:136

1

A*01:192

2

A*03:267

1

A*03:280

1

A*03:56

1

A*03:72

1

A*03:89

1

A*11:178

1

A*11:199

2

A*11:40

2

A*11:88

15

A*11:99

1

A*24:87

1

1

A*26:19

1

1

A*30:12

1

1

A*31:21

1

A*31:79

1

A*74:10

1

A*74:34

3

Total

38

3

5

21

2
4
38

3.5 Amino Acid Position in HLA-A Associated with RA
In HLA-A, an asparagine (N) at position 77 in the binding groove of the mature
protein is known to carry a high RA risk while the wild type is an aspartic acid (D)
(Han et al., 2014). Hence, codon 77 and the translated amino acid at this position were
determined for all samples. The amino acid at position 77 for control samples are listed
in Table 16 and patient samples in Table 17. A summary of the observed amino acids
at this position in patients and controls are provided in Table 18.
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Table 16: HLA-A amino acid at position 77 in control samples.
Sample
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C27
C28
C29
C30
C31
C32
C33
C34
C35

Amino acid
N/D
N
N
N
D
N
D
N/D
S
D
N
N
E
N/D
D
N
N
N/D
D
D
N/D
N/D
D
N
D
D
D
N
N/D
N
N
N
N/D
N/D
D
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Table 16: HLA-A amino acid at position 77 in control samples (Continued).
Sample
C36
C37
C38
C39
C40
C41
C42
C43
C44

Amino acid
D
N
D
D
N
N/D
N/D
N
N

Table17: HLA-A amino acid at position 77 in RA samples.
Sample
RA1
RA2
RA3
RA4
RA5
RA6
RA7
RA8
RA9
RA10
RA11
RA12
RA13
RA14
RA15
RA16
RA17
RA18
RA19
RA20
RA21
RA22
RA23
RA24
RA25
RA26
RA27
RA28

Amino acid
D
N
N
N
N
N
N
N
N
N
N
N/D
N/D
N
N
N/D
N
N
N
N/D
N/D
N
N
N/D
N
N
N
N
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Table17: HLA-A amino acid at position 77 in RA samples (Continued).
Sample
RA29
RA30
RA31
RA32
RA33
RA34
RA35
RA36
RA37
RA38

Amino acid
N
N
N
N
N/D
N
N
N/D
N
N

Table 18: Summary of HLA-A amino acid at position 77 in all samples.
Amino acid

Count (Control)

Count (RA)

N

17

29

D

14

1

N/D

11

8

Non N/D

2

0

Total

44
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Tables 16-18 shows the presence of the missense mutation at position 77 in
HLA-A samples where aspartic acid was changed to asparagine. This was observed to
be more frequent in patients than controls.

3.6 Other Locations in HLA-A with Higher Incidence in Patient

Based on the alignment obtained, frequency of variations in controls and
patients were calculated at all locations in exon 2 and exon 3 of HLA-A. A higher
incidence of variations was observed in patients at positions 56, where a arginine (R)
replaces a glycine (G) in the reference, and 76, where a glutamic acid (E) replaces a
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valine (V). To understand the significance of these, structural models of the wildtype
(Figure 27A) and mutants Gly56Arg (Figure 27B), Val76Glu (Figure 27C) and
Asp77Asn (Figure 27D) were generated using molecular modeling.

A

B

C

D

Figure 27: Three-dimensional models of wildtype and mutant HLA-A: (A) wildtype;
(B) Gly56Arg; (C) Val76Glu and (D) Asp77Asn.

3.7 Odds Ratio for the Three Observed Positions in HLA-A
To estimate the significance of the observed variations, Fisher’s exact test
was performed to compute the odds ratio and significance using R. The computed
values are shown in Table 19.
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Table 19: Variations in HLA-A with higher incidence in RA samples than control
samples.
Position

Variant

RA
(n=38)

Control
(n=44)

Odds Ratio
(OR)

p-value
(Fisher's test)

77

N

37

28

20.52

0.0001985

76

E

29

15

6.075

0.0001589

56

R

20

10

3.712

0.006273

3.8 Phylogenetic Analysis of Sequences
To understand the evolutionary relationship between samples, phylogenetic
trees were constructed using all HLA-DRB1 exon 2 sequences (Figure 28) and HLAA exon 2+3 sequences (Figure 29) using MEGA 6.
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Figure 28: Phylogenetic constructed from HLA-DRB1 exon 2 sequences.
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Figure29: Phylogenetic constructed from all HLA-A exon 2 & 3 sequences.
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3.9 Principal Component Analysis
Principal Component Analysis (PCA) of the DNA sequences was performed
in R using the adegenet package to reduce the dimensionality of the dataset and to
determine if the patient and control samples would distinctly cluster. PCA plots
obtained for principal component 1 versus principal component 2 for HLA-DRB1 is
shown in Figure 30 and HLA-A in Figure 31.

Figure 30: A plot of principal component 1 against component 2 obtained from PCA
of HLA-DRB1 exon 2 sequences. Red dots represent patient samples and blue dot
represents control samples.
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Figure 31: A plot of principal component 1 against component 2 obtained from PCA
of HLA-A exon 2 and 3 sequences. Red dots represent patient samples and blue dot
represents control samples.

3.10 Fixation Index
Fixation Index (FST) was computed for HLA-DRB1 and HLA-A sequences
using Arlequin. The obtained FST values were 0.02263 (p-value 0.04985) for HLADRB1 and 0.06811 (p-value 0.00098) for HLA-A.
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Chapter 4: Discussion

RA is a chronic heterogeneous autoimmune disorder of unknown etiology
resulting in inflammation in the cartilage, synovium, and bone (O'Rielly & Rahman,
2010). It is the second most predominant autoimmune disorder. Early diagnosis and
management is important for the notable improvement and favorable outcomes. The
absence of timely intervention lead to negative impact to patient health together with
a large societal burden (Kurko et al., 2013). RA usually appears after 30-40 years of
life and is more common in women which may be related to hormonal factors. RA is
reported to be present in 0.5-1% of the worldwide (Sangha, 2000; Trier et al., 2018).
Genetic factors often play a defining role in the pathogenesis of RA. Studies
have reported that the heritability of RA is from 50-60% (MacGregor et al., 2000).
There are multiple known loci that are associated with the risk of developing RA
(Bowes & Barton, 2008). Consequently, various genes have been studied as risk
factors for RA. Most of these genes are believed to be involved in immune system and
forms part of the major histocompatibility complex (MHC), known in the humans as
the Human Leukocyte Antigens (HLA). Importantly, this region is responsible for
approximately 30% of genetic susceptibility to RA (Bowes & Barton, 2008).
Specifically, among the HLA genes, HLA-DRB1 alleles are strongly associated with
RA (Jun et al., 2007; Lee et al., 2008). However, multiple studies have indicated that
other HLA genes are also linked with RA including HLA-A, HLA-B, and HLA-DPB1
(Coenen & Gregersen, 2009; Imboden, 2009). Interestingly, various alleles of HLADRB1 which are known to be associated with RA associate with what is known as the
SE region (Huizinga et al., 2005). This region is encoded by exon 2 of the HLA-DRB1
gene and corresponds to amino acids 70-74 in the mature protein. It has been

69
established that the acid-base properties of SE amino acid could have impact on the
interactions of HLA-DRB1SE motif (du Montcel et al., 2005). Alleles that have the
conserved SE amino acids sequences such as QKRAA, QRRAA, and RRRAA in the
third hypervariable region of the DRB1 chain between positions 70 to 74 are very
strongly associated with RA and is often used as a genetic biomarker for RA risk
association (Gregersen et al., 1987; Morgan et al., 2008). DRB1*04:01,*04:04,
*04:05, *04:08, *13:03, *01:01, *01:02, *14:02, *14:06, *15:01, *15:02, and 15:03
are the most studied alleles linked with RA but not all alleles display the same
magnitude of association (Gonzalez-Gay et al., 2002; Gorman et al., 2004; Imboden,
2009). SE allele's frequency varies between populations. It has been reported that
DRB1*04:01 and 04:04 were significantly associated with RA in Caucasian
populations, whereas Asian and Jewish RA patients were predominantly linked with
DRB1*04:05 and *01:01 alleles (Barnetche et al., 2008; Okada et al., 2014; Ollier &
Thomson, 1992). Based on this, the basic hypothesis of this study was that RA in
Emirati patients could also be associated with the high risk SE sequences. This is the
first study to our knowledge, to investigate the association of shared epitope with RA
in Emirati population. For this, 44 control and 54 RA Emirati samples were obtained
and evaluated from Fujairah Hospital after obtaining informed consent. HLA-DRB1
exon 2 of each subject was amplified and sequenced by using Sanger sequencing
method.
For the HLA-DRB1 gene, the most prevalent allele in the patient group and
control group was DRB1*16:02 which is considered as a low risk allele in the context
of RA. The high risk alleles DRB1*10:01 was found in only one patient and
DRB1*01:02 was found in 2 patients. Out of 43 control subjects 34 had the amino acid
sequence DRRAA as the SE, while this SE was observed in 35 of 54 patient samples
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(Tables 9 & 11). Studies have suggested that the DRRAA sequence which usually
corresponds to HLA-DRB1*16, *11, and *12 alleles, is a low risk allele and is not
associated with RA (du Montcel et al., 2005). Moreover, it was reported that amino
acid at position 70 influences the susceptibility to RA and the presence of aspartic acid
(D) at this position is believed to provide a protective effect as opposed to glutamine
(Q) or arginine (R) (Trier et al., 2018). Interestingly, RRRAA is a high risk allele and
mostly prevalent in Asian population (Mohan et al., 2017; Muazzam et al., 2013). This
SE was observed in only 1 out of 54 RA patients and was absent in control subjects.
Together, the high risk SEs QRRAA/RRRAA were observed in only 3 patients.
Surprisingly, the low risk SEs DRRRA/QARAA/DERAA were observed in 37 of 43
controls and 45 of 54 patients (Table 9 & 11). The shared epitope hypothesis was
formulated on the basis of a large body of evidence suggesting that the SE is the most
significant cause of RA that can be attributed to variations in the HLA genes
(Holoshitz, 2010). Putting together the data in this study, it appears that the low risk
SEs predominate both the patient and control samples and high risk SEs have low
incidence indicating that the HLA-DRB1 SE region is not the major cause of RA in
this sample of the population.
Looking outside the SE region of HLA-DRB1, it has been established that
specific amino acids at positions 11 and 13 could also impart high RA risk. These
amino acids line the base of the peptide binding groove (Scally et al., 2013). A valine
or leucine at position 11 (neutral) and/or a histidine at position 13 (basic) have been
associated with an increased risk of RA (du Montcel et al., 2005; Raychaudhuri et al.,
2012; Reynolds et al., 2014; Scally et al., 2013). Therefore, this region was examined
in both patient and control samples. However, in the vast majority of patient and
control samples, a proline was found at position 11 and an arginine at position 13 as
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shown in Tables 8 & 10, both of which have not been reported to increase the risk of
RA. However, a leucine or valine was observed in 3 out of 54 patients placing them at
a high risk of having RA. Nonetheless, very few of the RA cases could be attributed
to variations in the shared epitope and positions 11 or 13 indicating that HLA-DRB1
is likely not the major cause for RA in this population.
Setting HLA-DRB1 aside, among the HLA genes, variations in HLA-A has
also been shown to impart significant RA risk. A study of European seropositive RA
patients demonstrated an additional independent RA-risk in HLA-A amino acid at
position 77. A high risk was associated with asparagine at position 77 of the mature
protein (Han et al., 2014). Interestingly, this variation was observed to impart
protection in HIV controls (Morrison et al., 2007). To assess the association of HLAA gene with RA in this population, exon 2 and exon 3 of HLA-A was sequenced to
identify the allele types and genetic variations in this region. Out of 38 Emirati RA
patients, 37 had missense mutation at amino acid 77 where aspartic acid was mutated
into asparagine (D>N) whereas, this variation was present in only 28 healthy controls
(Table. 18). This placed it at a significant risk for RA in this population with an OR
of 20.52 (p-value 0.0001985) (Table 19). Interestingly, two missense variations Val76Glu and Gly56Arg - with an OR of 6.075 (p-value 0.0001589) and 3.712 (pvalue = 0.006273), respectively were also observed in this population (Table. 19). The
Val76Glu mutation was observed in 29 out 38 RA patients whereas in controls it was
present in only 15 individuals out of 44. Similarly, variant Gly56Arg was observed in
20 patients while only 10 controls had this variation. Amino acid 77 is critical to the
function of HLA-A since it is present in binding groove. The amino acid aspartic acid
has overall negative charge, while asparagine is a polar amino acid and mostly involve
hydrogen bonding with other residues. Therefore, this variation could disrupt the
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binding ability of HLA-A. Position 76 is adjacent to this in the binding groove. Valine
is a non-polar amino acid while glutamic acid is negatively charged. Like position 77,
a hydrophobic to charged amino acid at location 76 is likely to affect the binding
characteristics of the binding groove. Structural models illustrate the location and
proximity of this amino acid in the binding groove (Figure 27). Position 56 is located
near the peptide binding groove of HLA-A (van Deutekom & Keşmir, 2015). A
Gly>Arg results in a change from a small achiral amino acid to a large charged amino
acid. This is likely to affect protein flexibility and interactions due to the change in
size and charge of the amino acid change. While these variations may have a role in
RA it is also likely that this may increase an individual’s risk towards other comorbid
conditions. These variations have not been reported in the literature. Hence, further
studies are required to clearly elucidate the role of these variations.
Finally, to evaluate if the genetic sequences of patients and controls cluster
separately into one or more groups, several kinds of analyses were performed.
Phylogenetic analysis, PCA and fixation index all indicated that patients and controls
form a homogeneous group and there is no clear clustering at the gene level (Figures
38-31). Therefore, it appears that variations at specific locations are key to a higher
risk of RA.
While this study evaluated two HLA genes that account for the vast majority
of RA cases, isolated variations in HLA-B and HLA-DPB1, both at position 9, have
also been linked to RA (Han et al., 2014; S. Raychaudhuri et al., 2012). However, due
to time and funding limitations, these could not be investigated in this study. Apart
from the HLA region, a few other genes have also been associated with RA in this
region (Yamamoto et al., 2015). A detailed evaluation of these regions with either
conventional Sanger sequencing or Next Generation Sequencing (Chen et al., 2018;
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Hosomichi et al., 2015) could be employed to get a comprehensive understanding of
how genetic variations could play a role in RA in this population. Genome wide
association studies (GWAS) could also be considered using a large sample size to
elucidate genetic variations associated with RA in this population.
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Chapter 5: Conclusion

RA is widely attributed to an autoimmune response. Variations in several HLA
genes are associated with an increased risk for RA. Two specific HLA genes HLADRB1 and HLA-A that account for the vast majority of RA cases associated with the
HLA region were investigated in this study. The SE hypothesis suggests that specific
sequences between amino acids 70-74 of the HLA-DRB1 protein is the leading risk
factor. Furthermore, positions 11 and 13 of this protein were also associated with RA.
However, this study found extremely low incidence of these high risk variations in the
samples collected from Fujairah Hospital in the UAE. Asparagine at position 77 of
HLA-A is another leading RA risk factor. In the samples studied, 37 of 38 patients had
the asparagine at position 77 suggesting that this variation could be a stronger
biomarker for RA in this population. To confirm this finding, and to extend it further,
evaluation of a larger sample of both patient and controls is recommended.
Furthermore, other HLA and non-HLA genes could also be evaluated to find their
association with RA in the Emirati population. Genome-wide approaches and the
impact of the environment may also be necessary to gain a holistic understanding of
genes, pathways and interactions that impart significant risk of RA in the population
of UAE.
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